Background. Patients hospitalized with hematologic malignancy are particularly vulnerable to infection. The impact of reported beta-lactam (BL) allergy in this population remains unknown.
reported BL allergy in hospitalized patients with hematologic malignancy remains unclear [4, 7, 21, 22 ]. An Australian cohort of 198 general cancer patients noted worse clinical outcomes in patients with an antibiotic allergy label; however, the study did not specifically investigate the impact of the BL allergy label and hematologic malignancy [21] . We hypothesized that among adult inpatients with hematologic malignancy requiring antibiotics, reported BL allergy is associated with adverse clinical outcome.
METHODS

Design and Exposure
To evaluate the outcomes associated with reported BL allergy in patients with hematologic malignancy, we conducted a retrospective cohort study of patients with the diagnosis of hematologic malignancy admitted to the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center between 1 January 2010 and 31 December 2015. Here, BL allergy refers to patients who have a nonmonobactam BL allergy label in their electronic health record (EHR). Patients with reported nonmonobactam BL allergy without other concomitant antibiotic allergy or BL-only allergy (BLOA) were defined as the exposed group. The unexposed group was defined as patients with no BL allergy (NBLA), but these patients could have other antibiotic allergies. To avoid potential confounding effects of concurrent antibiotic allergies and to isolate the impact of BLOA, patients with both BL allergy and other antibiotic class allergies were excluded in the exposed group.
Specific antibiotic class allergies were collected using the EHR label. Additional subgroup analyses, defined a priori, were performed to compare the patients with the penicillin class allergy-only (POA) group and the cephalosporin class allergy-only (COA) group.
Patients and Setting
The study included all hospitalized patients aged ≥18 years with a diagnosis of hematologic malignancy who received systemic antibiotic of any duration. Hematologic malignancy was defined as leukemia, lymphoma, or myeloma diagnoses identified through International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) and ICD-10 codes. Systemic antibiotics were defined as antibacterial medications received through intravenous or oral route for the treatment of suspected or confirmed infection. Patients who received only antiviral, antifungal, perioperative, or prophylactic antibiotics were excluded. For patients with multiple qualifying hospital encounters, only the first encounter was included.
Data were provided by the institutional data analytic center, Penn Data Store. Selective manual chart review was performed for quality control. The University of Pennsylvania Institutional Review Board approved the study.
Outcomes
The primary outcome was hospital LOS after the first dose of antibiotic. Secondary outcomes included mortality (30 and 180 days after first antibiotic), 30-day readmission, intensive care unit (ICU) admission, ICU LOS after first antibiotic, and complications including acute kidney injury (AKI, per the Kidney Disease Improving Global Outcomes Guideline [23] ) and C. difficile infection diagnosis identified through ICD-9 and ICD-10 codes. Antibiotic use information data included drug class and duration and time to first antibiotic after admission. We also collected total initial encounter inpatient billing charge to examine the economic impact of BLOA.
Baseline Characteristics and Comorbidities
To account for baseline comorbidities in the analysis, data on general demographics, cancer type, severity of illness index on admission [24] , neutropenia, and history of hematopoietic stem cell transplant (HSCT) were collected. Presence of febrile neutropenia was not specifically reported because of the inability to identify this condition using aggregate data.
Statistical Analyses
Median LOS after first antibiotic was compared between BLOA and NBLA groups using a cumulative incidence function. Bivariable and multivariable analyses were performed using competing-risks regression analysis with in-hospital death included as a competing risk. Multivariable models were developed to determine the association between BLOA and LOS. Variables were included in the model if they were associated with LOS in univariate analysis (P ≤ .20) [25] , and they were maintained in the final model if they remained significantly associated with the outcome when manual backward deletion was used. Type of malignancy, neutropenia, and admission severity of illness index were identified a priori as potential important factors and so were maintained in the model. Collinearity was evaluated and, if variables were collinear, only 1 was maintained in the model. A subdistribution hazard ratio (SHR) and 95% confidence interval (CI) were calculated to evaluate the strength of associations. SHR <1.0 is associated with reduced likelihood of discharge and prolonged LOS.
For the secondary outcome of 30-day mortality, univariate and multivariable analyses were conducted to identify factors associated with 30-day mortality using logistic regression analysis. Multivariable model-building occurred as described for the primary outcome.
For descriptive statistics and other secondary outcomes, categorical variables were compared using the χ 2 or Fisher exact test, as appropriate. Continuous variables were compared using the students t or Wilcoxon rank sum test, as appropriate. For all calculations, a 2-tailed P value of .05 was considered statistically significant. All calculations were performed using Stata version 14.1 (StataCorp., College Station, Texas).
RESULTS
Cohort Characteristics
Cohort demographics, comorbidities, therapy, and outcomes are summarized in Table 1 , Conversely, 3668 (78.5%) patients had no history of BL allergy label (NBLA), including 3031 (64.9%) with no history of antibiotic allergy and 637 (13.6%) with allergy to other non-BL antibiotic classes. Patients with BLOA had similar age, racial, and body mass index distribution compared to the NBLA group (Table 1) . However, in contrast to the NBLA group, among patients with BLOA, more were likely to be female and there was a prevalence of leukemia, HSCT, and neutropenia. The median admission severity of illness index score was similar between the groups (3 of 4).
Primary and Secondary Outcomes
Patients with BLOA had significantly longer median LOS following the first dose of antibiotic therapy compared to patients with NBLA (11.3 days vs 7.6 days, P < .001; Table 1 ) and had a lower probability of discharge at any given time (SHR = 0.83, 95% CI = 0.77-0.90, P < .001; Table 2 and Figure 1 ). In terms of secondary outcomes, patients with BLOA had significantly higher mortality rate both at 30 days (7.6% vs 5.3%, P = .017) and 180 days (15.8% vs 12.2%, P = .013), 30-day readmission rate (19.2% vs 15.1%, P = .008), C. difficile rate (17.7% vs 11.6%, P < .001), and median total initial inpatient encounter charge ($223 046 vs $173 256, P < .001) compared to patients with NBLA (Table 1 ). There were no significant differences in AKI and ICU admission or LOS after administration of the first antibiotic between the 2 groups.
Antibiotic Use
There were significant differences in antibiotic use between patient groups (Table 1) . Antibiotic susceptibility patterns of Enterobacteriaceae and Pseudomonas at the study sites support the use of BLs as the preferred agents, particularly cephalosporins and carbapenems, due to less favorable toxicity profiles and susceptibility patterns of alternative agents (Supplementary Figure 1) . Patients with BLOA were less likely to receive penicillins and cephalosporins and more likely to receive non-BL antibiotics. While 89.3% of NBLA patients received nonmonobactam BL, 63.3% of patients with BLOA still received nonmonobactam BL (P < .001; 17.9% penicillin, 54.8% cephalosporin, and 15.0% carbapenem). Patients with BLOA also required a greater median number of antibiotic classes (3 vs 2 classes, P < .001) and a longer median duration of antibiotic therapy (9 vs 6 days, P < .001).
There were no significant differences in median time to first antibiotic administration after admission between the groups (Supplementary Table 2 ). However, for BLOA patients who received a non-BL gram-negative agent, the time to first antibiotic was significantly longer than for BLOA patients who did not receive a non-BL gram-negative agent (1.6 vs 0.61 days, P < .001).
Hospital LOS: Primary Outcome
Results of univariate analyses of the association between LOS and selected variables are shown in Supplementary Table 1. After adjusting for potential confounders including neutropenia, leukemia, and severity of illness, the significant association between BLOA and LOS (ie, longer LOS) remained (SHR = 0.91, 95% CI = 0.83-0.99, P = .026; Table 3 ).
We performed exploratory analyses to examine the effect of antibiotic choice on the association between BLOA and clinical outcomes. Given that antibiotic choice was likely in the causal pathway, we did not include it in the multivariable model but did examine antibiotic choice separately to observe its impact on the association between BLOA and LOS. The association between BLOA and LOS does not hold when the receipt of non-BL gram-negative agents is accounted for, particularly aminoglycosides, (SHR became 1.07, 95% CI = 0.97-1.18, P = .162) or non-BL gram-positive agents, particularly vancomycin (SHR became 0.97, 95% CI = 0.88-1.06, P = .464). These findings suggest that the association between BLOA and longer LOS may be driven, at least in part, by the use of non-BL antibiotics. In addition, among the BLOA patients who did not receive BL, there was a more negative impact on LOS in our exploratory analyses (SHR became 0.78, 95% CI = 0.71-0.85, P < .001), suggesting a potential negative impact of withholding BL in BLOA patients.
30-Day Mortality: Secondary Outcome
The multivariable model results used to examine the association between BLOA and 30-day mortality are shown in Table 4 . The negative association remained significant even after we adjusted for other potential confounders of neutropenia, leukemia, and severity of illness (odds ratio = 1.44, 95% CI = 1.00-2.00, P = .05).
Subgroup Analyses
A total of 436 (9.3%) and 155 (3.3%) patients reported exclusive allergy to penicillin class (POA) and cephalosporin class (COA), respectively ( Table 2) . Carbapenem-only allergy was rare (5 patients, 0.1%). Both POA and COA were associated with increased LOS; compared to 7.6 days for the NBLA group, median LOS for patients with POA was 8.0 days (P = .03) and 18.5 days for patients with COA (P < .001; Supplementary Table 3 and Supplementary Figure 2) . Compared to the NBLA group, both POA and COA subgroups demonstrated higher C. difficile rate, encounter charge, and antibiotic use (Supplementary Table 3 ). In addition, POA was associated with higher 30-day mortality rate (7.6% vs 5.3%, P = .046), and COA was associated with longer ICU LOS (4.1 days vs 3.1 days, P = .044). COA appeared to have a greater negative impact than POA on median total hospital LOS, total initial inpatient encounter charge, antibiotic classes required, and duration of inpatient antibiotic therapy (P < .001). Of note, there was a significantly higher prevalence of leukemia in the COA group (67.8%) compared to 35.2% for the POA group (P < .001) and 36.3% for the NBLA group (P < .001).
The rate of BL use was significantly lower in the POA group (56.7%) compared to the COA (84.5%, P < .001) and NBLA (89.3%, P < .001) groups. POA patients received significantly less penicillin (8.3%) compared to COA (38.7%, P < .001) and NBLA (26.5%, P < .001) patients. COA patients received less cephalosporin (65.8%) compared to NBLA patients (78.6%, P < .001) but more than POA (49.3%, P < .001) patients.
DISCUSSION
In this cohort, we noted a relatively high prevalence of antibiotic allergy label (35.1%, including 21% to BL, 16.5% to penicillin, and 7.1% to cephalosporin) compared to previous studies on general inpatients [9, 10, 12, 21] . These findings suggest BL allergy label may be seen more frequently in patients with hematologic malignancies, especially those with leukemia, possibly due to greater antibiotic exposure.
BLOA-allergy label in hospitalized patients with hematologic malignancies was associated with increased LOS in univariate and multivariable analyses. We also noted worse secondary outcomes in patients with BLOA, including readmission, mortality, C. difficile rate, total hospital charge, and alternative antibiotic usage. While many of the observed adverse outcomes associated with BLOA were consistent with outcomes found in prior studies, our study has quantified the impact of BLOA in patients with hematologic malignancies and, for the first time, demonstrated mortality disadvantage associated with this allergy label, which remained significant after correcting for comorbidities [7, 8, 10, 12, 21, [26] [27] [28] . A prior study of general cancer patients found worse outcomes with antibiotic allergy but did not isolate the specific impact of BL allergy label in patients with hematologic malignancy and did not demonstrate increased mortality [21] . Our findings may reflect the impact of immunodeficiency and comorbidity associated with the hematologic cancer, especially in the setting of infection and suboptimal antibiotic choices [3, 22, 29, 30] .
Possible reasons for increased LOS for patients with BLOA may include lower treatment efficacy with non-BL agents, increased adverse events related to non-BL antibiotics, and delay in receipt of antibiotics [7, 15, 18, 20] . Results of our exploratory analyses suggest that the association between BLOA and longer LOS may be driven by the use of non-BL antibiotics. Less favorable susceptibility patterns of non-BL antibiotics (eg, fluoroquinolones) provide potential evidence for less favorable treatment outcomes [31] [32] [33] . It also appears that patients with BLOA have higher rates of C. difficile, potentially contributing to increased LOS. Delay in receipt of antibiotics, as was noted in patients with BLOA who received a non-BL gram-negative rod agent, may also contribute to worse outcomes. Despite their allergy labels, a large portion of patients with BLOA and COA received BL antibiotics. However, we did not collect specific information on antibiotic appropriateness, side chain, subclass, or cephalosporin generation, which may have influenced antibiotic choice. In addition, we did not investigate what proportion of patients received inpatient skin testing or antibiotic desensitization, which may also affect choice of antibiotic. Even with this finding, patients with BLOA received BL at a lower rate than those without BLOA, received broad-spectrum antibiotics such as carbapenems, and required more classes of antibiotics [14] .
The median total inpatient billing charge for patients with BLOA ($223 046), especially COA ($319 945), was higher than for patients with NBLA ($173 256). We did not collect the billing charge by medication, procedures, or details, so additional study is needed. However, greater hospital charge could be related to higher complication rate and prolonged LOS [29] . Because few studies have investigated the economic impact of drug allergy label, our findings contribute to evidence that BLOA is associated with worse economic outcomes [20, 34] . Because of the adverse clinical and economic impacts of BLOA label, interventions such as history taking, documentation, and, when appropriate, antibiotic skin tests and drug challenges may be beneficial when targeted to patients with hematologic malignancies [8, 15, 17-19, 22, 35, 36] .
Predefined subgroup analysis revealed a differential clinical impact between POA and COA, which, to our knowledge, has not been investigated previously. Although both POA and COA contributed to the negative impact of BLOA, COA seemed to confer more negative impact on outcome than POA. This result may be partially related to the higher prevalence of leukemia, neutropenia, and gram-negative sepsis in hematologic malignancy where cephalosporins are frequently preferred as firstline therapy. While an adequately powered prospective study to investigate COA and POA with multivariable analysis and adjusting for confounders is important to confirm these findings, our data suggest that COA may be especially harmful in this patient population. Therefore, interventions should focus not only on appropriate penicillin labeling and delabeling but also on novel interventions for cephalosporin allergy label, such as cephalosporin skin testing and assessment of the risk of cross-reactivity between different cephalosporins [6, 37] .
There are potential limitations that should be considered when evaluating the results of this study. First, the retrospective cohort study design limits the inferences that can be drawn from the associations observed due to confounding bias. We attempted to account for potential confounders through predefined sets of known factors that may confound results. Second, the allergy labels in our cohort were collected from the hospital her, and we did not scrutinize the nature or accuracy of the allergy history. However, this study was intended to reflect actual practice, where antibiotic use is often based on documented or reported history [7, 20, 36] . Third, in order to avoid confounding effects of another concurrent antibiotic allergy label, we excluded patients with BL allergy with other antibiotic allergy labels from the analysis. This exclusion allowed us to isolate the effect of BL allergy only but may have underestimated the impact. Fourth, use of receipt of systemic antibiotic therapy as our inclusion criteria rather than evidence of infection may have included uninfected patients who received antibiotics and omitted some infected patients who did not receive antibiotics. However, use of antibiotics has been accepted as a reasonable surrogate to identify patients with infection at centers with infection surveillance [5, 38, 39] .
CONCLUSIONS
In hospitalized patients with hematologic malignancy that requires antibiotics, patients with reported BL allergy have worse clinical outcomes than those without BL-allergy label, likely due to differences in antibiotics received. This study highlights the clinical importance and potential cost effectiveness of accurately labeling and delabeling BL allergy through clinical history and allergy evaluation.
